- Pharmaceutical Technology
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

BMS acquires biopharma firm MyoKardia for $13.1bn

Through the transaction, BMS secured MyoKardia’s cardiovascular drug, mavacamten. Credit: jesse orrico on Unsplash.